- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Atkins steps down as InSight CEO
InSight Health Services of Newport Beach, CA, last month announced the resignation of its president and CEO, Larry Atkins. The company said that its chairman, Frank Egger, will take on Atkins’ duties until a permanent replacement is found. Atkins
InSight Health Services of Newport Beach, CA, last month announced the resignation of its president and CEO, Larry Atkins. The company said that its chairman, Frank Egger, will take on Atkins duties until a permanent replacement is found. Atkins became president and CEO of InSight in 1996, when the company was formed out of a merger between imaging services firms Maxum Health and American Health Services (SCAN 3/13/96). Under his leadership, InSight doubled its annual revenues.
The company has also combined its operations into two geographic areas, with Brian Stone leading the eastern region and Michael Madler leading the western region. InSights central region operations will be absorbed into the two new areas. Both Stone and Madler have been promoted to executive vice president positions and will report to InSights president and CEO.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
